Analysis of Prescribed and Compounded Anticancer Drugs at Phenikaa University Hospital

Abstract

This study was conducted to analyze the anticancer drug formulary and evaluate compounding outcomes at Phenikaa University Hospital during the period from October 2025 to March 2026 using a retrospective descriptive design. The study results showed that the total expenditure on anticancer medications was VND 13.88 billion, accounting for 21.69% of the hospital’s total drug expenditure. Among these, monoclonal antibodies and antibody–drug conjugates accounted for the highest proportion of drug costs (60.66%), particularly Pembrolizumab. This finding reflects the current trend in oncology treatment, shifting from conventional chemotherapy toward modern therapeutic approaches with greater efficacy in improving survival outcomes across various malignancies.Analysis of the chemotherapy compounding formulary revealed that the total value of centralized compounded medications was 10.32 billion VND, the residual drug waste after compounding was valued at 620.228 million VND, accounting for 5.93% of the total prescribed anticancer drug expenditure. These findings indicate a substantial discrepancy between the prescribed doses and the actual administered doses to patients (5.93%). Therefore, centralized compounding and dose sharing of anticancer agents are essential strategies to minimize drug wastage, reduce occupational exposure risks for healthcare personnel, and mitigate environmental contamination.